Big Pharma Company Outlook to 2016

NEW YORK, Jan. 18, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0760606/Big-Pharma-Company-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Introduction

This analysis examines the outlook for companies in Datamonitor's Big Pharma peer set. The report encompasses insight into key strategic themes across the group of companies and identifies sales trends using 6-year prescription pharmaceutical sales forecasts for all the companies covered.

Features and benefits

* Gain insight into Big Pharma companies strategic outlook across the next 6 years* Analyze sales forecasts by company, therapy area, lifecycle stage, and molecule type.

Highlights

Strategic insight into the prospects for Big Pharma companies over the next six years. Picking out key trends across the companies and comparing performance using a variety of cuts of forecast sales.

Your key questions answered

* Benchmark companies outlook against key rivals across Datamonitor's Big Pharma peer set* Assess how - based on organic growth projections - Novartis will be positioned as the industry leading prescription pharma player by 2016

Key findingsOverview of the Big Pharma peer setBig Pharma prescription sales performance, 2004–16The Big Pharma company outlook to 2016INTRODUCTIONData sourcing[Missing title]Further readingSTRATEGIC INSIGHTBig Pharma growth rate to slow significantly over 2010–16BIG PHARMA OUTLOOK TO 2016Key findingsOverview of Big Pharma to 2016Big Pharma prescription pharma sales performance, 2004–16Big Pharma landscape, 2010–16Big Pharma company analysisBig Pharma launch/core/expiry analysisBig Pharma therapy area analysisBig Pharma molecule type analysisAPPENDIXReferencesDatamonitor reportsExchange rates

More  

Check our  

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker